NCT01847196终止不适用
A Multi-center, Early Feasibility Study of the Angel® Catheter in Critically Ill Subjects at High Risk of Pulmonary Embolism
BiO2 Medical8 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2013年11月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 6
- 试验地点
- 8
- 主要终点
- Number of Adverse Events Occuring for All Evaluable Subjects
研究概览
简要总结
The primary objective of this clinical trial is to obtain initial insights into the safety of the Angel® Catheter in critically ill subjects with high risk of venous thromboembolism (VTE) disease AND who are not receiving pharmacological thromboprophylaxis.
详细描述
STUDY ENDPOINTS
- Primary Endpoints:
a. Initial Insights into Safety
- Success in delivery, maintenance and removal of the Angel® Catheter.
- Incidence and seriousness of all adverse events.
- Incidence of device or procedure-related adverse events.
- Secondary Endpoints:
- Evaluation of the separate and combined functions of the IVC filter and the central venous catheter device.
- Evaluate investigative site's ability to comprehend the procedural steps (Per the Insertion Procedure, the Repositioning Procedure, and the Removal Procedure)
- Evaluate operator challenges with device use (human factors).
- Evaluate success and challenges encountered in conducting a pivotal trial in critically ill patient population - including but not limited to Informed Consent and enrollment.
ENROLLMENT AND SUBJECT SAMPLE SIZE
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •(Must Answer YES to all Inclusion Criteria):
- •Subject or legally authorized representative is willing and able to provide written informed consent, AND
- •Subject is 18 years or older, AND
- •Subject is currently admitted OR to be admitted to the Intensive Care Unit (ICU) within ≤36 hours of screening, AND
- •Subject has a clinical need for a Central Venous Catheter, and/or the subject has an existing Central Venous Catheter that has been in place for <36 hours before Angel® Catheter placement, AND
- •Subject is considered at high risk for PE and meets ONE of the following criteria:
- •Subject has multiple trauma with at least ONE of the following:
- •Severe head injury
- •Head injury with a long bone fracture
- •Spinal cord injury with paraplegia or quadriplegia
- •Multiple (≥2) long bone fractures
- •Multiple (≥2) long bone fractures with pelvic fracture
- •Pelvic fracture requiring open fixation
- •Critically ill subject in the Intensive Care Unit with at least ONE of the following:
- •Hemorrhagic or ischemic stroke
- •Multiple organ failure
- •Active or recent bleeding (within the past 2 weeks)
- •Severe sepsis
- •Lower extremity DVT
- •Anticipated ventilator requirement of greater than one week
- •Critically ill subject requiring temporary (≥48 hours) interruption of medical thromboprophylaxis (prophylactic anticoagulation)
排除标准
- •(Must Answer NO to All Exclusion Criteria):
- •Subject is pregnant or lactating
- •BMI = (Weight (lb) x 703)/(〖Height〗^2 (inches)) > 45; BMI may also be calculated at http://nhlbisupport.com/bmi/bminojs.htm
- •Subject has a pre-existing IVC filter in place
- •Subject is currently receiving prophylactic anticoagulation, other than aspirin or Plavix. Specifically, the subject is receiving any of the following medications: heparin, low molecular weight heparin, factor Xa inhibitors (i.e. xabans), Coumadin, and thrombin inhibitors.
- •Subject has a diagnosis of pulmonary embolism
- •Subject is participating in another clinical investigation
- •Subject has known hypersensitivity to any of the components of the Angel® Catheter, specifically Nitinol (nickel and/or titanium)
- •Subject has functioning pelvic renal allograft on the only side available for device insertion
- •Subject has undergone a surgical procedure involving the femoral vein or pelvic veins through which the device must be inserted
- •Anatomic inability to place the Angel® Catheter (including a history of thrombosis of venous system on side of proposed access)
- •Anticipated survival ≤48 hours
结局指标
主要结局
Number of Adverse Events Occuring for All Evaluable Subjects
时间窗: From the time of subject enrollment through study exit (7 days post-removal or hospital discharge, whichever occurs first), for up to 37 days
All Adverse Events (AEs) occurring throughout the study will be identified and characterized by seriousness, relationship to the investigational device and/or procedure, and whether un/anticipated.
次要结局
- Device Performance(From the time of Angel® Catheter insertion through Angel® Catheter removal, for up to 30 days)
研究者
研究点 (8)
Loading locations...
相似试验
进行中（未招募）
不适用
GORE Glaucoma Drainage Implant Clinical Study Dominican RepublicPrimary Open-angle GlaucomaNCT05557058W.L.Gore & Associates30
招募中
不适用
LUMENS-1 EU EFS CIPAneurysm CerebralBifurcationUnruptured Intracranial AneurysmSaccular AneurysmBrain AneurysmNCT06761365LuSeed Vascular LTD.30
终止
不适用
The Study for Evaluate of Safety and Efficacy of Vein of Marshall RF AblationPersistent Atrial FibrillationNCT05854238Tau-MEDICAL Co., Ltd.4
已完成
1 期
A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)Advanced or Metastatic Solid TumorsNCT05594043Merck Sharp & Dohme LLC39
招募中
1 期
RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic CancerPancreatic Cancer Non-resectablePancreatic Cancer MetastaticPancreatic CancerNCT04338763Rise Biopharmaceuticals, Inc.48